Yvan Samson

The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia

Steven E. Lipshultz, Nader Rifai, Virginia Dalton et al. · New England Journal of Medicine · 2004 · 619 citations

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Steven E. Lipshultz, Rebecca E. Scully, Stuart R. Lipsitz et al. · The Lancet Oncology · 2010 · 442 citations · Full text

Drug Safety, Hematological Malignancy, Oncology +9

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

Albert Moghrabi, Donna E. Levy, Barbara L. Asselin et al. · Blood · 2006 · 401 citations · Full text

Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

Elly Barry, Daniel J. DeAngelo, Donna Neuberg et al. · Journal of Clinical Oncology · 2007 · 191 citations

Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol

Steven E. Lipshultz, Amy Giantris, Stuart R. Lipsitz et al. · Journal of Clinical Oncology · 2002 · 134 citations

Heart Failure, Pediatric Heart Disease, Cardiovascular Pharmacology +18